Akili (AKLI) Scheduled to Post Quarterly Earnings on Thursday

Akili (NASDAQ:AKLI – Get Rating) will be posting its quarterly earnings results after the market closes on Thursday, May 11th. Analysts expect Akili to post earnings of ($0.18) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Akili Price Performance

Shares of NASDAQ AKLI opened at $1.60 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.37 and a quick ratio of 10.37. The firm has a 50-day moving average of $1.44 and a 200 day moving average of $1.55. Akili has a 1 year low of $0.86 and a 1 year high of $37.58.

Get Akili alerts:

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upped their price target on shares of Akili from $2.00 to $3.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 25th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Akili presently has an average rating of “Moderate Buy” and an average target price of $3.75.

Hedge Funds Weigh In On Akili

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC acquired a new stake in Akili in the 3rd quarter valued at $32,000. Geode Capital Management LLC lifted its holdings in Akili by 55.0% during the 4th quarter. Geode Capital Management LLC now owns 38,504 shares of the company’s stock worth $43,000 after buying an additional 13,657 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in Akili in the 4th quarter valued at approximately $237,000. Millennium Management LLC grew its holdings in shares of Akili by 246.5% in the 4th quarter. Millennium Management LLC now owns 229,257 shares of the company’s stock worth $257,000 after acquiring an additional 163,094 shares during the last quarter. Finally, Alyeska Investment Group L.P. boosted its position in Akili by 183.6% during the fourth quarter. Alyeska Investment Group L.P. now owns 772,390 shares of the company’s stock valued at $865,000 after purchasing an additional 500,000 shares during the last quarter. 77.97% of the stock is owned by hedge funds and other institutional investors.

Akili Company Profile

(Get Rating)

Akili, Inc, a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.

Featured Stories

• Get a free copy of the StockNews.com research report on Akili (AKLI)
• Starbucks Stock Becomes a Value Play
• Kraft Heinz Recovery Gains Momentum 
• Here’s Why AMD’s Weak Guidance Is A Blessing In Disguise
• BP Shares Sold Off After Earnings: Here Is What Upset Markets
• Will Forced Divesture Of Grail Boost Illumina Shareholder Value?

Receive News & Ratings for Akili Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akili and related companies with MarketBeat.com's FREE daily email newsletter.